Log In
Print this Print this

HyQvia, Ig infusion 10%

Also known as: formerly HyQ

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionSubcutaneous formulation of IV Gammagard, an IgG antibodies plasma-based therapy, and rHuPH20, a recombinant human PH20 hyaluronidase enzyme
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationImmunodeficiency
Indication DetailsTreat primary and secondary immunodeficiencies in patients ages 0-18; Treat primary immunodeficiency disorder (PID); Treat primary immunodeficiency disorders and myeloma or chronic lymphocytic leukemia (CLL) with severe secondary hypogammaglobulinemia and recurrent infections
Regulatory Designation U.S. - Standard Review (Treat primary immunodeficiency disorder (PID))
PartnerHalozyme Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today